Israel’s Mixiii-Biomed, the prestigious three-day life science and biomed conference now in its 17th year, attracted over 6,000 #healthcareprofessionals, #scientists, engineers, and investors from 45 countries this week, highlighting industry trends and looking at the future of the world’s #digitalhealthindustry, as well as biotech and medical devices.
It was also an opportunity for the participants to experience Israel’s #lifescience-focused tech and innovation firsthand as well as encourage #Israeliacademicinstitutions, research facilities, and health-and-science-focused #startups to connect and collaborate with international health industry leaders. The event also featured an exhibition showcasing 45 startups developing #medicaldevices, #drugdeliverysystems, #nanotechnology, and #biomed and #pharmaceuticalproducts. The exhibition was sponsored by the #IsraelInnovatio Authority, the support arm of the Israeli government in the national development of #industrialR&D.
Among the 45 startups chosen, out of dozens, according to conference organizers, companies that generated conversation included Consis Medical, an “early-stage medical device company, devoted for the development of novel, single-use and self-propelled endoscopes,” Raziel Therapeutics, a Jerusalem-based startup that has developed a new localized injection that melts fat cells, and Bubble, a platform that eases menopausal symptoms in women like hot flashes and night sweats through an immersive virtual reality experience.
A panel of of judges, which included Israeli industry leaders like Dr. Ami Applebaum, chairman of the Israel Innovation Authority and chief scientist of the Israel Ministry of Economy, Anya Eldan, as well as vice president of the Israel Innovation Authority’s startup division, Karin Mayer Rubinstein, chose 10 of the companies for a #startupcompetition, where they presented their concepts to the crowd and the panel of Israeli industry leaders.
The competing companies were Alpha Tau Medical, a solid #cancer #tumortreatment company, wearable brain sensor firm Neurosteer, #eye-trackingdevice company NovaSight, #bloodcountdevice maker PixCell Medical, MRI software company Brainvivo, #artificialcornea developer CorNeat Vision, #temperaturestabilizer TempraMed Israel, #motorrestoration medical device company E-Motion Medical, eating behavior monitor Barimote, and #microgravity services company SpacePharma.
The judges chose PixCell Medical and CorNeat Vision were the #winning companies, which Applebaum said “exemplify differentiated #technology and solid global strategy, serving as a beacon of excellence for the well-being of humanity.”
On Thursday, Dr. Ami Appelbaum, chairman of the Israel Innovation Authority and Chief Scientist at Israel Ministry of Economy and Industry, said that PixCell Medical,and CorNeat Vision were the winning companies.
The company’s main product is HemoScreen, a low-cost portable hematology analyzer which can perform a complete #bloodcount (CBC) at the point-of-care, using disposable cartridges that need no maintenance or calibration. HemoScreen requires a drop of blood from the finger, and within five minutes analyzes 20 standard CBC parameters, including red blood cells and five white blood cell types. It identifies anomalous cells and hemoglobin levels.
The HemoScreen relies on viscoelastic focusing, a physical phenomenon discovered at the Technion, Israel Institute of Technology, in which as blood flows through a micro-channel, some cells migrate to the center of flow and align perfectly into a single cell layer. This brings them in focus and enables them to be optically detected and analyzed. Identification and classification of the cells is achieved using machine learning and machine vision algorithms.
CorNeat Vision is developing an artificial cornea – the CorNeat KPro implant. The CorNeat KPro implant is a patented synthetic cornea that utilizes advanced cell technology to integrate artificial optics with the ocular tissue that is already present. The implants are produced using nanoscale chemical engineering that stimulates cellular growth. The CorNeat KPro is combined with a new surgical procedure to provide an efficient, comfortable and affordable remedy for millions of people with cornea-related visual impairments.
PixCell Medical is developing a technology to create a point-of-care (POC) hematology analyzer, or blood count device. Point-of-care is a term used for the point of time at which a clinician can deliver solutions and products while with the patient, at the time of care.
Israel Innovation Authority CEO highlights Israel’s digital health plan
Aharon Aharon, the Israel Innovation Authority’s CEO opened the second day of the conference by presenting Israel’s prowess in healthcare and innovation as well as reaffirming the Israeli government’s commitment to promote digital health through a new initiative set to pour $275 million into the local digital healthcare industry.
The plan, approved by the Israeli cabinet, was first announced in March by Prime Minister Benjamin Netanyahu at the World Economic Forum Annual Meeting in Davos, Switzerland in January. Netanyahu said at the time that Israel would partner with multinational software company SAP over the next five years for a program to digitize the personal health records of Israeli citizens, and is designed to develop personalized and preventive medicine with the use of AI and machine learning tools for more tailored diagnoses and treatment.
Aharon said digital healthcare is now considered “the main growth engine of the Israeli economy,” and that Israel’s global leadership in information and communication technology (ICT) give it an edge to transform the industry in a groundbreaking way.
According to Aharon, the Israeli government is looking to contribute $15 million to health regulation, $70 million to encourage more R&D in the field, $10 million to human capital, and $180 million to health and research infrastructures. He emphasized the government-based incentives for Israeli researchers abroad to return to the country, as well as biotech and tech incubators, and other well-funded funded programs.
Aharon said that one reason Israel has an advantage in the digital health arena is that it holds electronic medical records for 98 percent of the population and gives researchers access to a wealth of usable data for R&D purposes. While this has raised some privacy concerns, the government believes its overall projects, which include the establishment of a national center for genetic screening, and advancing joint projects between the Israeli health system and world health systems, among other plans, will be beneficial.
“This $275 million government initiative will further strengthen Israel’s leadership in the $6 trillion global digital health industry, leveraging Israel’s technological prowess in big data analytics, AI, and machine learning to develop efficient and personalized medicine,” he tells NoCamels in an email. “This change will shift the entire healthcare industry towards medicine that focuses on prevention and personalized cures.”
The Israel Innovation Authority, he says, “will leverage this government digital health initiative and ICT capabilities together with Israel’s local, world-renowned scientific research talent to bring anchor pharma companies to Israel and facilitate therapeutic and diagnostic capabilities.”
Aharon also praised the country’s “strong scientific capabilities,” pointing to Israel having more PhDs per capita than any other nation in the world, ranking 3rd in the world with intellectual properties (inventions, literary and artistic works; and symbols, names and images used in commerce) per capita, and with 33 percent of all Israeli scientists in the life sciences field.
Speakers highlight Israel’s digital healthcare innovation
The conference had a large number of international and local speakers whose talks, presentations, and panels were divided into nine tracks that focused on digital health, IoT, and big data in medicine; next-generation oncology treatments; brain health; personalized diagnostics and treatments; fighting rare genetic diseases using novel therapeutic approaches; nanomedicine and its role in new medical therapeutics; academic research to industry; cutting-edge medical device technologies; and novel clinical trial designs and technologies to accelerate drug development.
MIXiii-Biomed 2018 Exhibition.Credit: Kenes Exhibitions
Many of these speakers, while highlighting their own research and company achievements, also referred to the incredible innovation coming out of Israel’s healthcare industry.
Bruce Rosengard, vice president of global external innovation and medical devices at US multinational pharma and packaged goods giant Johnson & Johnson made sure to commend Israel’s MedTech, saying, “There’s more innovation here in medical devices than anywhere on the planet.”
Israel’s digital healthcare industry had much to celebrate during the three-day event. Ahead of the conference, organizers released numbers about the industry which noted that the industry had a “compounded annual growth (CAGR) of 10 percent from 2008 to 2017.”
The 1,200 Israeli life science companies currently in existence raised a $1.2 billion in VC funds in 2017, with over 135 investment deals, according to the report, marking a whopping 41 percent increase compared to 2016. This was due in part to two significant exits — the acquisition of clinical-stage pharmaceutical company NeuroDerm by Mitsubishi Tanabe for $1.1 billion, and the acquisition of heart valve tech maker Valtech by Edwards Lifesciences for $1 million with an upfront payment of $340 million. In 2016, Israel raised $850 million in 137 deals.
The report also highlighted growing trends in the industry, which Aharon emphasized in his presentation, including big data, the influence of AI on medical diagnosis, personalized medicine and more.
BrainQ Raises $8.8M To Treat Stroke And Spinal Cord Injury With AI
May 16, 2018 | Israeli medtech startup BrainQ, developing AI-powered technology to treat neurodisorders, has announced it has raised $5.3 million in a funding round to cap their total funding to date at $8.8 million. Investors from investors that include Norma Investments, the Tokyo-based fund IT-Farm, and Qure Ventures, Israel “first fund focused on exclusive on digital health” under equity crowdfunding platform OurCrowd, and other strategic angel investors. BrainQ says it will use the funding to further develop its non-invasive simulation device for commercialization in various markets. Funds will also be used to support clinical trials and grow their database. BrainQ is currently developing technology that uses AI algorithms to identify spectral patterns in a patient’s brain waves (known as “electroencephalogram” or “EEG.”) These patterns are then translated into a customized electromagnetic treatment for disabilities that arise from neurodisorders such as stroke and spinal cord injury. The AI-powered technology comes from developing one of the largest known Brain Computer Interface (“BCI”)-based EEG databases for motor tasks. BrainQ was named one of the four companies in the world to transform healthcare with AI last year. It’s currently participating in Google’s Launchpad Studio program in San Francisco. It’s also working with Google’s Israel accelerator. BrainQ is one of the key investments for OurCrowd Qure, a new fund launched in 2016 by OurCrowd – Israel’s first exclusive digital health fund and appearing at the MIXiii-BIOMED 2018 conferencefor the Digital Health, IoT, and Big Data track.